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The World Health Assembly, in May 1991,
approved a resolution about the global elimination of
leprosy as a public health problem by the year 2000,
and defined this elimination as the reduction of
prevalence to 1 case or less per 10,000 inhabitants.
The resolution took into account the considerable
progress achieved with multidrug therapy (MDT),
with great reduction of prevalence as well as the
substantial support of nongovernmental organizations
and the fact that many countries were giving higher
priority to leprosy control.
“The estimative number of leprosy cases world-
wide in 1991 was 5.5 million. This figure shows a
marked decline from the 10-12 million cases estimated
earlier and suggests that it is the success of MDT that
brought such a drastic reduction1.”
Noordeen2 analyzed in detail the relevant
findings and the justifications for the elimination
strategy as well as the limitations of MDT.
The possibility of reaching the elimination goal
depends mainly on three factors and related conditions.
1. ANTILEPROSY DRUGS AND MDT
It is known that the advent of sulfones3 repre-
sented a remarkable progress, with revolutionary
changes in leprosy control: abolishment of leprosaria
and shift from inpatient to outpatient care. Early diag-
nosis and early chemotherapy in dispensaries became
the most important method of control, supported by
health education and relevant measures. For more than
30 years International Congresses of Leprology and
* Reprinted, with permission, from the International Journal of Leprosy 62: 284-292, 1994.
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WHO Expert Committees on Leprosy considered sul-
fone the drug of choice in the treatment of leprosy.
Gradually it was recognized that their main shortcom-
ing was their slow effect (clinical, bacteriologic and
histologic) in the multibacillary forms of leprosy. Be-
cause of the long period of treatment required for lep-
romatous (L) and borderline (B) patients, a large pro-
portion of them became irregular or lost sight of. To
this must be added the high proportion of inactive cases
who relapsed, due to the persistence of bacilli, and also
the development of resistant Mycobacterium leprae
strains, as confirmed by mouse foot pad inoculation.
The WHO/MDT scheme (dapsone + rifampin +
clofazimine) is at present considered the best one: it
increases the efficacy of treatment and reduces the
risk of development of resistant strains of M. leprae.
Attention should be drawn to Dietrich’s, et al4
prospective randomized multicentric trial. They
compared monotherapy (dapsone, DDS) and combined
therapy: DDS + rifampin (RMP) and DDS + rifampin
+ isoniazid (INH) + prothionamide in 307 LL and BL
patients. After 3 years, treatment was stopped and 216
patients finally could be evaluated. Several treatment
parameters were adopted including relapses and
patients with established DDS resistance in the mouse
foot pad. All of them did not show any significant
differences among the three treatment regimens.... It
is concluded that DDS is very efficient, rifampin or
the combination with rifampin, INH and prothionamide
do not add substantially to the treatment success....
However the final conclusion can only be made after
the termination of the 5-year treatment-free period.
In another trial by Irudayaraj and Aschhoff 5,
132 untreated leprosy patients (77 LL + 55 BL) were
randomized into three different regimens: 1) DDS;
2) DDS + RMP and 3) RMP + Isoprodian and treated
continuously for 3 years. Pre- and post-treatment bi-
opsies were inoculated into the mouse foot pad.  “The
BI reduction between the regimens was not signifi-
cant. The percentages of bacteriologically negative
patients after 3 years period in these regimens were
not different from each other.  Eighty patients (63%)
remained still BI positive at the end of the study.  About
96% of the strains from bacteriologically positive pa-
tients after 3 years’ treatment did not multiply in the
mouse foot pad, indicating so far a uniform kill after
this period. No relapses have been encountered.”
In a THELEP trial, in connection with UNDP
and WHO6 combined drug regimens were studied in
215 previously untreated patients with lepromatous
leprosy in Bamako, Mali, and in Chingleput, India.
“The regimens-daily RMP, DDS and clofazimine
(CLOF) or prothionamide (PTH); a single initial large
dose of RMP together with daily DDS; and daily
CLOF or PTH for the first 3 months, together with
daily DDS and RMP, either in a single initial large
dose or 900 mg once weekly – were administered for
2 years. During this time, biopsy specimens were ob-
tained, and the recovered M. leprae were inoculated
into thymectomized-irradiated (TR) mice for detec-
tion of persisters. In addition, periodically the bacte-
rial index (BI) and logarithmic index of biopsies (LIB)
were measured, the patients were examined clinically
and observed for side effects, and a number of  labo-
ratory tests were carried out.
“Despite the widely varying ‘strength’ of the
experimental regimens no differences were demon-
strated among the regimens, with respect to the fre-
quency with which persisting M. lerae were detected,
clinical response, and adverse reactions, with two ex-
ceptions.”
It should be noted that with the regimens of a
single initial large dose of RMP together with daily
DDS for 2 years the results were similar to those of
other combinations of drugs, including one with daily
RMP and CLOF! Side effects should also be taken
into account.
Further results of these studies are expected with
great interest, mainly regarding relapses, as well as the
findings of other trials concerning MDT and new drugs.
Ofloxacin, minocycline and clarithromycin are being
tried in pilot studies with promising results, but have
lower bactericidal activity than rifampin. It is hoped
that other MDT schemes with the new drugs will have
greater impact on the disease, shortening the period
of treatment and reducing the rate of relapses.
Notwithstanding the findings of the three
trials, the WHO/MDT as well as other combinations
must be applied because of the risk of development
of M. leprae-resistant strains with monotherapy. It
should be recognized that, in spite of the progress
achieved, at present we are far from having an ideal
single drug or combined regimens for leprosy
treatment. The efficacy of MDT may be improved by
replacing CLOF with ofloxacin or another drug. CLOF
is not accepted by a certain number of patients due to
the pigmentation it causes.
So far the similarity of findings of various regi-
mens of MDT and DDS alone does not suggest that
the drastic decline of prevalence since 1982 is due to
the success of MDT.  Instead, two other causes should
be considered. When MDT was adopted (1982) the
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duration or treatment was considerably shortened: 6
months for the paucibacillary (PB) cases, 2 years for
the multibacillary (MB) cases. Previously the dura-
tion was 3-5 years for the former and 5-10 years or
more for the latter. The anticipated release from con-
trol of all cases – PB and MB – automatically caused the
decrease of prevalence. The Figure shows WHO data
regarding mass survey (Myanmar) or random sample
surveys in several countries (Argentina, Cameroon,
Nigeria, The Philippines and Thailand) with total
prevalence rate as well as lepromatous (L) + border-
line (B), tuberculoid (T) and indeterminate (I). These
are much higher for T and I cases than L cases. The
considerable shortening of the treatment period and
follow up caused a drastic reduction of total preva-
lence and for each form of leprosy. To this should be
added that WHO/MDT was implemented with an im-
provement of the control program in each area. When
this is accomplished, even with monotherapy, appre-
ciable results have been achieved in several areas of
the world. The prevalence was also greatly reduced
because patients were released from control after long
periods of treatment (usually 5-10 years for LL cases).
The prospective of obtaining such a decrease of
prevalence with monotherapy had been indicated by
Martinez and Bechelli7 regarding tropical Africa, in
the areas where the socioeconomic situation is favor-
able and there is an effective control program.  Since
there is, mainly in Africa, a very high proportion of
tuberculoid cases – in whom spontaneous regression
of lesions occurs in 60%-80% of cases8,9 and relapses
are rare – an effective campaign
could stabilize and reduce the
prevalence to a variable degree
in a relatively short period.
Relapses.  A high propor-
tion of inactive L cases treated
only with sulfone have re-
lapsed10/16.
Quagliato, Bechelli and
Marques15 observed in inactive
L patients still on sulfone therapy
that up to 3 years after bacterial
negativity and clinical inactivity
the number of relapses was small
and increased substantially after
5, 9.5 or more years up to 30%.
The Marchoux Chemo-
therapy Study Group17 studied
the frequency of relapses in MB
patients after stopping treatment
with rifampin-containing com-
bined regimens. It was confirmed that relapses oc-
curred late after completion of treatment (ultra-short
courses, 3 of 6 months duration, 1 of 12 months, 2 of
24 months). A great majority of relapses described in
the paper have been confirmed by mouse foot pad in-
oculation. Among 437 eligible patients, 384 have been
seen at least once later than 12 months after complet-
ing treatment. Out of these 384, 255 had not received
antileprosy treatment previously and 129 (33.6%) had
received treatment.
The overall relapse rate among 384 patients was
17.7%. Among patients followed up for more than 1
year, relapse was 17. 1% after 7 years and 25% after
10 years, higher among those with a BI ≥ 5 (21.3%).
“The risk of relapse was significantly smaller among
those which achieved smear negativity (p < 0.01).
However achievement of smear negativity does not
guarantee that the patients will not relapse”. “...Be-
cause of the late appearance of relapse patients should
be followed-up for at least 7 to 10 years after com-
pleting chemotherapy. Only after a long period of fol-
low-up may one draw final conclusions with respect
to the efficacy of any RMP-containing combined regi-
men, including WHO/MDT... Therefore the relative low
relapse among patients treated with WHO/MDT must
be interpreted with caution pending longer follow-up.
Because millions of leprosy patients have been or
currently are being treated with the WHO/MDT regi-
men, we strongly suggest that the MB patients, espe-
cially those whose BI is still high after completion of
treatment, be closely followed-up.”
Figure 1 - Prevalence, L, I and T rates per 1000 in Myanmar (BCG trial area) and in
some other areas of the world (WHO random sample surveys)24. Argent = Argentina;
Camer = Cameroon; Niger = Nigeria; Philip = The Philippines; Thail = Thailand.
Countries
0
5
10
15
20
25
30
35
   L + B
   T
    I
   Total
374
LM Bechelli
During the last 15 years Pattyn18 and cowork-
ers have been involved in studies on short MDT regi-
mens for the treatment o MB leprosy: the duration of
treatment varied from 104 weeks to 52, 34, 13 and 4
weeks. All regimens were triple-drug regimens, ex-
cept for one double-drug regimen and one with four
drugs. “Overall, relapses occur more frequently among
patients with a higher BI at the start of the treatment....
The WHO regimen applied to previously untreated,
highly bacilliferous patients... is followed by a cumu-
lative rate of 10% at 5 years.”
He concluded that “to evaluate treatment regi-
mens in MB leprosy it is necessary to follow-up pa-
tients until 9-10 years after the end of treatment . . .”;
the risk of relapses increases with time. Furthermore,
“the absence of relapse during the first 3 years does
not exclude high relapse rates later on.” Regarding
the dormant bacilli he adds: “For the time being it
seems logical to administer to those patients who have
been treated in the past with whatever combined regi-
mens and who are ‘inactive’, a short course of a few
days of a bactericidal drug such as RMP once a year,
for 10 years, after the end of the treatment to elimi-
nate any possible bursts of dormant bacilli.”
In the 14th International Congress of Leprosy
(1993), the Workshop on Chemotherapy “suggested
the fixed duration regimen may prove to be inadequate
in previously untreated LL patients with a high bacterial
load, and counselled caution in the widespread adop-
tion of 2 years fixed duration treatment of WHO/MDT
until further data are available. It also noted that many
relapses are occurring late and, therefore, five years”
post-treatment follow-up appears to be very inad-
equate, 8-10 years being the minimum required”.
From the findings mentioned, it appears that a
significant proportion of MB patients are expected
to have a late relapse after stopping the 2-year
WHO/MDT. Therefore to reduce to a minimum the
relapse rate and the risk of a late recrudescence of the
endemic, MB cases should be treated until the subsid-
ence of all signs of activity and achievement of smear
negativity. The minimum period of regular treatment
should be extended from 2 to 3-5 years, according to
the severity of the disease and bacterial load. The post-
treatment follow up should be of about 10 years.
WHO/MDT in PB leprosy (6-month treat-
ment). In PB leprosy spontaneous regression of the
skin lesions occurs in a high proportion of cases, from
53% to 88%8,9. Although only a certain proportion of
PB cases would really need MDT, the impossibility
of identifying them – unless lepromin testing is per-
formed – and the risk of disabilities render the treat-
ment of all of them obligatory.
According to Pattyn18, to be effective in PB
leprosy a dose of RMP should be associated with
several other doses of RMP, either daily for 6 days or
weekly for 8-12 weeks or monthly for 6 months, or
with daily DDS for 1 year.
From the studies of Nadkarni, Grugni and Kini19
and Katoch, et al.20 it appears that PB patients treated
for 6 months by WHO/ MDT had a lower proportion
of inactivation and a higher percentage of deterioration
in contrast to a higher proportion of inactivation
and very low rate of deterioration with WHO/MDT
(6 months) followed by DDS (6 months). Besides,
unfavorable evolution occurred mainly in the first 2-3
years of follow up. These findings lead to the
conclusion that WHO/MDT should be carried out at
least for 1 year and treatment stopped only when there
is no sign of activity.  A follow-up period of 2-3 years
is advisable mainly for patients who initially had three
or more lesions.
Incidence. To achieve a real decline of the
endemic it is essential to get a significant and lasting
decrease of the incidence. This takes a long time, and is
not accomplished unless the rate of MB cases and,
consequently, the load of infectiousness is substantially
reduced. Otherwise, after an apparent success of the
campaign and a possible attenuation of the control
measures, a reactivation of the endemic would occur
in the long term, as observed with tuberculosis in recent
years.
According to Noordeen2, “Although MDT can
drastically reduce prevalence of existing cases, its ca-
pacity to reduce incidence of new cases, at least in the
first years of MDT implementation, is rather limited.”
 The decline of incidence takes a relatively long
term, as noted in an excellent control project in Central
African Republic. Nebout21 reported the data regarding
prevalence and incidence from 1958 to 1980, before
the use of MDT. The population was 1,250,000
inhabitants in 1962 and 2,050,000 in 1981. The number
of registered cases was 65,388 in 1958 (66 per
thousand), the highest in the world; in 1980 the rate
was 5.7 per thousand. Almost 50% of the patients were
regularly treated (≥ 75% of the dose prescribed was
taken), 27.4% intake of 40%-74% and 25.6% less than
40%. The rate of new cases per thousand was 2.37 in
1960, 0.54 in 1970, 0.34 in 1978, 0.33 in 1979, and
0.37 in 1980. However, the incidence rates per 1000
of L cases have slightly increased: 0.025 (1960), 0.028
(1970), 0.032 (1978), 0.035 (1979), and 0.035 (1980).
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Before WHO/MDT was introduced, the
findings of the WHO Leprosy Advisory Team in
Africa (northern Nigeria; north, central and south
Cameroon) in a random sample survey25 showed that
even in countries with fairly good case-finding
programs new cases amounting to 7 5% of the number
of registered cases were detected.
The difficulties for implementing WHO/MDT
and for the development and success of control pro-
grams are related to characteristics of the disease
itself; poor health infrastructure in many countries,
adequate in only a few; limitations of treatment and
preventive methods; education and cultural back-
ground; socioeconomic and other factors (section 3).
Furthermore, in the scale of priorities leprosy comes
after several diseases, especially AIDS, malaria, tu-
berculosis, trypanosomiasis, cholera, schistosomiasis,
STD and others, depending on the countries and
areas.
According to Nakajima26, WHO Director Gen-
eral, “AIDS is rapidly becoming a most serious threat
to human existence. WHO estimates that 8. 10 mil-
lion adults may currently be infected with the human
immunodeficiency virus. More than half of these will
develop AIDS within ten years and most will die....
The global malaria situation has become critical in
recent years.... The disease is endemic in some 100
countries.... In West Africa 18 million people are in-
fected with onchocerciasis.... Widespread malnutrition
and improper nutritional practices are evident, even
in areas where food is plentiful. . . .”
In fact, especially where leprosy is highly preva-
lent, the health service has to deal also with diseases
of higher endemicity and/or high mortality rates.
Funds available are very often limited and
frequently full advantage of resources is not taken
because of inadequate planning and programming.  It
is difficult or impossible to increase leprosy budgets
proportionately, and the speed of work is thus reduced,
to the great detriment of the development of the
general program.
It should be added that in many endemic areas
there is a shortage of doctors or most of them are not
interested in working in leprosy control projects.
Salaries are usually low or not considered high enough
to encourage staff to devote themselves fully to their
work. Furthermore, health campaigns have been
hampered by the appointment of personnel, even in
supervisory posts, who lacked the necessary technical
qualifications.
The above factors have been analyzed in detail
by Bechelli27,28 and Martinez and Bechelli8.
WHO/MDT side effects. Taking into account
the data concerning MDT in 3507 patients in the
period between 1986 to 1988, Ramu22 stated that side
effects occur only occasionally. However, a few cases
had hepatotoxicity, oliguria, acute renal failure, flu
syndrome, exfoliative dermatitis, methemoglobinemia,
shock, night blindness, lymphadenopathy. Hemolysis
occurred in 17 cases; red and black pigmentation and
ichthyosis were common.
Our University Hospital (Hospital das Clínicas)
has received some patients with very serious adverse
reactions to MDT: hepatotoxicity, jaundice, renal fail-
ure. One of them died, and the autopsy showed liver
necrosis and hemorrhage, disseminated intravascular
coagulation and gastric erosions.
It is important that staff get adequate training
to recognize MDT side effects and to take relevant
action. Hospital facilities are required to attend the
patients with serious adverse reactions. It seems that
these often occur at the third intake of rifampin.
2. DIFFICULTIES IN IMPLEMENTING MDT AND
CONTROL PROGRAMS
(This topic is interlinked with section 3.
Socio-economic, cultural and other factors in leprosy
endemic areas (discussed later).
The difficulties may be easily evaluated, con-
sidering the table from LEP News1. The number of
registered cases was 3,087,788, including 584,412
new cases. The estimated number of leprosy cases
worldwide in 1991 was 5.5 million. The number of
cases on MDT was 1,295,640, roughly 42% of the
registered cases. This means that in spite of the WHO,
governments and nongovernmental organizations’
praiseworthy efforts, 58% of registered patients were
not yet receiving MDT nor were the estimated
2,400,000 undiagnosed cases.
Marked progress was achieved in 1992 23. “The
proportion of registered cases being treated with MDT
at the time of this report is about 49% and the
cumulative MDT coverage since this strategy was
introduced has reached 22%. More than 5.3 million
were or are being treated with MDT....”
From a WHO epidemiological study in an effi-
cient control project in Myanmar 24 it appears that 13%
of L cases, 48% of B, 43% of I and 54% of T cases
were undiagnosed. The PB patients are less important
in spreading the disease but 5%-10% of untreated I
cases could evolve to L or B and become contagious.
Also a certain proportion of undiagnosed and untreated
I and T patients could develop disabilities.
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Millan29 reported that 10 years after WHO had
recommended MDT, this could be applied only to a
minority of patients in Africa. However certain coun-
tries, members of OCCGE, have achieved consider-
able progress in the last 2 years to improve the MDT
coverage. This varies from 8.4% in Mali to 97% in
Benin. With MDT the prevalence rate in eight
OCCGE countries dropped from 4.97% in 1982 to
1.09% in 1990. However, it seems that in the same
period the detection rate continued to be between
1.2% and 1.8%.
Millan29 also stresses that “...the application
constraints of MDT raise very difficult operational
problems that hinder its generalization. To be effective
the MDT coverage should be preceded, as done in
Benin and Senegal, by an intense preparation implying
the reorganization of duties, actualization of archives
and training of relevant staff.”
In the investigation by the Marchoux Chemo-
therapy Study Group17 regarding relapses, 50% of their
324 patients had been lost to follow up 5 years after
completion of treatment. It is probable that in routine
campaign work the proportion would he higher.
In India, according to Ramu22 “... irregularity
in intake of self administered clofazimine has been
occurring due to poor patient compliance as well as
irregular drug supply .... Patients who are taking
self-administered drugs irregularly would be on
rifampicin monotherapy.  There is a great danger of
emergence of rifampicin resistance in them and
rifampicin resistance has already been documented
in 39 cases relapsing under rifampicin monotherapy.”
(Grosset, et al. 1989).
Languillon30 considers that MDT is “relatively
possible” in urban areas but not in rural zones.  In the
French-speaking countries good roads among villages
allow the mobile teams to treat and control the patients.
However, after 6-8 months of treatment they improve
and become irregular or stop the drugs. This does not
happen in the pilot areas where MDT has a special
surveillance. It is also noted that during the period of
agricultural activities patients do not attend regularly.
Languillon mentions the ILEP programs, 620 in 88
countries: out of 831,000 patients only 32% were
receiving MDT.
When only dapsone was used Laviron31
reported that in French-speaking Africa, 10% to 60%
of the patients were under regular treatment, around
60% were not yet detected, and about 50% were out
of control (“lost sight of ”).
With WHO/MDT what is the proportion of MB
cases that in fact have taken the drugs irregularly over
2 years? Probably a significant proportion of them
are taking self-administered drugs irregularly. For
decades this has been a constant difficulty in leprosy
projects and also in the control of other chronic
diseases. Thus the efficacy of treatment would be
reduced while the risk of relapse would be increased.
3. SOCIOECONOMIC, CULTURAL, EDUCATION,
DEMOGRAPHIC, POLITICAL AND RELATED
FACTORS IN LEPROSY-ENDEMIC AREAS
There is an intimate relationship between the
health situation and the economic level which, in its
turn, depends on very different ecological, demo-
graphic, historical, cultural and sociological factors.
A leprosy endemic is present in developing countries
or areas.
In the highly industrialized countries leprosy
had disappeared or is practically absent, even before
the advent of sulfones. In addition, in these countries
“imported” cases have not disseminated the disease.
This spreads where the inhabitants face unfavorable
socioeconomic and related conditions: penury, hunger,
malnutrition, high infantile mortality, unemployment,
low minimal salary, inflation, recession, poor housing,
slums (“favelas”), promiscuity, lack of hygiene, illite-
racy, no family planning, ecological degradation, cor-
ruption, political instability, rebellion, internal war, etc.
In an editorial in the World Health Forum, the
WHO Director General Nakajima26 analyzes health
and development in the 1990s: “In spite of improvements
in the world health situation, the disparity between
developed and developing countries and even between
population groups in some countries remains great.
The high rate of avoidable maternal mortality in
many developing countries, and the difference in
the expectancy between the rich and the poor, are
unacceptable.... Notwithstanding some social indicators
show that even at low-income levels, impressive
human development can be achieved. Yet we still have
a long way to go to realize the goal of health for all
people, everywhere.... The issue is how to stem the
rising tide of socio-economic conditions that deprive
millions of fellow human beings of the basic
conditions for health, and for leading a decent and
productive life.... Accompanied by the lack of
economic growth, rising unemployment, diminishing
expenditure on other health-related sectors (such as
education, water supply and sanitation) and the natural
disasters that beset certain countries and regions, this
means that millions of people remain critically
vulnerable at the start of the new decade....”
Prospects of leprosy elimination
377
The above facts and considerations give the
picture of the difficulties that WHO and governments
are facing and have to overcome in order to reach the
objectives of different health campaigns, including the
elimination goal of leprosy by the year 2000.
Tuberculosis may be mentioned as an example. With
BCG and the advent of new drugs since the 1950s, the
disease was under control. However, due to adverse
conditions, including the spreading of AIDS, there has
been a significant increase in the incidence and number
of deaths32.
Taking into account what was considered in
sections 1, 2 and 3, it does not seem possible to achieve
the global elimination of leprosy as a public health
problem by the year 2000. In the next 7 years it will
be extremely difficult, if not impossible, for all of the
endemic countries to reach the desirable socio-eco-
nomic level and overcome all the unfavorable condi-
tions. The alternative would be the availability in the
very near future of an efficient vaccine and/or a very
effective and easily administered drug, as much as
possible cheap and free from serious side effects, ca-
pable of reducing to a very short period the duration
of treatment.
Even if the elimination goal established by the
World Health Assembly in May 1991 is not reached,
the praiseworthy efforts of WHO, governments,
nongovernmental organizations and specialists shall
be of great benefit to countries and populations.
In light of the data presented, the following
conclusions can be drawn:
• In randomized trials MDT regimens were not
significantly superior to DDS alone. Furthermore, a
significant proportion of late relapses have been
observed in MB patients. The present findings do
not confirm that the drastic reduction of leprosy
prevalence, from 10-12 million to 5.5 million since
1982, was due to the success of WHO/MDT. When
this was adopted the duration of treatment was
considerably shortened. The anticipated release from
control of all treated cases caused, automatically, a
considerable reduction of prevalence.
• Late relapses have been observed in a significant
proportion of MB patients, especially those with a
high BI when stopping MDT. To reduce to a
minimum the relapse rate and the risk of
recrudescence of the endemic, MB cases should be
treated until the subsidence of all signs of activity
and the achievement of smear negativity. The
minimum period of regular treatment should,
therefore, be extended from 2 to 3-5 years, according
to the severity of the disease and bacterial load. The
post-treatment follow up should be about 10 years.
• Unfavorable evolution was more often observed in PB
patients submitted to only 6 months of WHO/MDT.
Thus, it is necessary to carry out regular treatment
with MDT for at least 1 year, and the treatment should
be stopped only when there is no sign of activity. A
follow up of 2-3 years is then required, mainly for
patients who initially had three or more lesions.
• Considerable progress has been achieved in the
therapy of leprosy and its control in the last 50 years,
and the WHO/ MDT and other MDT regimens are
recommended because of the risk of the development
of resistant strains of M. leprae with monotherapy.
However, the present situation regarding the control
of leprosy with WHO/MDT is similar to that of
syphilis treated by arsenical + bismuth + mercury
until 1943 when penicillin was introduced. So far
there is not an ideal single drug or combined regimen
for leprosy therapy.
• Many unfavorable conditions in endemic areas hinder
the implementation of WHO/MDT and the control
of leprosy and other diseases.
• In view of the above, it does not seem possible to
achieve the global elimination of leprosy as a public
health problem by the year 2000, unless an ideal
drug and/or vaccine becomes available in the very
near future. With BCG and effective drugs,
tuberculosis was under control for a long period but,
in recent years, its morbidity and number of deaths
have increased significantly. Syphilis has not yet
been eradicated in half a century in spite of the
effective and simple treatment with penicillin.
It is expected that the endeavors of WHO and
institutions and scientists concerned with the problem
may lead, in the near future, to the discovery of the
ideal drug and/or vaccine, the only way of controlling
leprosy in a relatively short period, as yaws was prac-
tically eradicated and smallpox eradicated, in the most
adverse conditions, in two remarkable WHO programs.
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RESUMO: Nesta revisão crítica, a perspectiva de eliminação global da lepra é analisada como
dependente de três fatores: 1) eficácia da poliquimioterapia anti-hanseniana; 2) dificuldades na
implementação da terapia farmacológica e outros programas de controle; 3) condições não-médi-
cas em áreas endêmicas. Baseando-se nestes fatores, emerge uma visão pessimista relacionada
ao objetivo da OMS de eliminar a lepra do planeta no ano 2000.
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